price
About
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Stock ticker
- AZN
- Company
- AstraZeneca PLC
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- 21
- Launch date
- May 12, 1993
- Listed exchange
- NYSE
Financials
Summary: AZN reported Revenue of 15.38B (+6.41%), meeting expectations; EPS of 2.63 (+20.64%), beating expectations.
Dividends
AZN conversion tables
 |  |
|---|---|
| 0.5 AZN | 81.89 USD |
| 1 AZN | 163.78 USD |
| 5 AZN | 818.92 USD |
| 10 AZN | 1,637.84 USD |
| |
|---|---|
| 0.5 USD | 0.0030528 AZN |
| 1 USD | 0.0061056 AZN |
| 5 USD | 0.030528 AZN |
| 10 USD | 0.061056 AZN |
More to explore
FAQ
AZN is trading at $163.78, -0.26% over the last 24 hours. Track live moves on the price chart at the top of this page.
The AZN stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. AZN is currently trading at $163.78, -0.26% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on AZN price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. AZN's P/E ratio is currently 24.71 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from AZN; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against AZN's historical range and other companies in the Healthcare sector.
AstraZeneca PLC's market cap is currently 255.23B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.